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Abstract
Background:  Renal epithelial tumors are morphologically, biologically, and clinically
heterogeneous. Different morphologic subtypes require specific management due to markedly
different prognosis and response to therapy. Each common subtype has characteristic
chromosomal gains and losses, including some with prognostic value. However, copy number
information has not been readily accessible for clinical purposes and thus has not been routinely
used in the diagnostic evaluation of these tumors. This information can be useful for classification
of tumors with complex or challenging morphology. 'Virtual karyotypes' generated using SNP
arrays can readily detect characteristic chromosomal lesions in paraffin embedded renal tumors
and can be used to correctly categorize the common subtypes with performance characteristics
that are amenable for routine clinical use.
Methods: To investigate the use of virtual karyotypes for diagnostically challenging renal epithelial
tumors, we evaluated 25 archived renal neoplasms where sub-classification could not be definitively
rendered based on morphology and other ancillary studies. We generated virtual karyotypes with
the Affymetrix 10 K 2.0 mapping array platform and identified the presence of genomic lesions
across all 22 autosomes.
Results: In 91% of challenging cases the virtual karyotype unambiguously detected the presence
or absence of chromosomal aberrations characteristic of one of the common subtypes of renal
epithelial tumors, while immunohistochemistry and fluorescent in situ hybridization had no or
limited utility in the diagnosis of these tumors.
Conclusion: These results show that virtual karyotypes generated by SNP arrays can be used as
a practical ancillary study for the classification of renal epithelial tumors with complex or ambiguous
morphology.
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Background
Each year in the United States, there are approximately
31,900 cases of kidney and upper urinary tract cancer that
account for approximately 3% of adult malignancies, and
result in more than 11,900 deaths [1]. The most common
types of renal epithelial tumors are clear cell renal cell car-
cinoma (RCC) (75%), papillary RCC (10%), chromo-
phobe RCC (5%), and benign oncocytoma (5%)[2].
Correct pathological classification is critical for prognosis,
management, therapy, and eligibility for clinical trials.
Classification of renal epithelial tumors is primarily based
on cytologic appearance, cell type of origin, and growth
pattern. Morphological distinction among the renal cell
tumor subtypes is generally straightforward after routine
pathologic examination of the tissue. However, a subset
of cases are ultimately diagnosed as renal cell carcinoma,
unclassified, due to the presence of non-specific features
that can be seen in all of the subtypes (such as granular,
oncocytic or sarcomatoid morphology) [3] or the pres-
ence of more than one subtype in the same tumor [2].
Specific genetic abnormalities have been found in the dif-
ferent types of renal cell tumors and have been well char-
acterized in the literature [4]. More than 98% of clear cell
RCC show deletions in the p arm of chromosome 3, while
papillary RCC usually presents with trisomies of chromo-
somes 7 & 17 and/or loss of chromosome Y. Chromo-
phobe RCC is characterized by a hypodiploid
chromosomal complement with monosomies of chromo-
somes 1, 2, 6, 10, 13, 17 and 21. Oncocytoma shows
either normal chromosomes or copy number alterations
in chromosome 1. Although the chromosomal alterations
that characterize each subtype of renal epithelial neo-
plasms have been known for some time, this knowledge
has not been routinely utilized in the diagnostic evalua-
tion of these tumors. More than a decade ago, Steiner and
Sidransky proposed the use of loss of heterozygosity
(LOH) analysis with microsatellites to detect specific
chromosomal deletions in renal tumors [5]. However,
these assays have not been incorporated into clinical prac-
tice. Metaphase karyotyping can be used to detect these
characteristic chromosomal lesions but it is not routinely
used for diagnosis of renal tumors because fresh tissue is
typically not available and solid tumors often grow poorly
in culture. In addition karyotypes from solid tumors are
especially challenging for cytogeneticists due to complex
rearrangements and less than optimal banding patterns.
Given the clinical relevance of accurately classifying
patients for prognostic implications and therapeutic deci-
sions, there is a need for diagnostic tools that reliably
detect and quantify genetic lesions that are diagnostic for
each subgroup of renal epithelial neoplasms.
Several techniques have been utilized for genome-wide
scanning of chromosomal aberrations in renal tumors,
including comparative genomic hybridization (CGH)[6],
array CGH [7], and SNP arrays [8]. Array CGH has been
used to accurately classify RCCs by histologic type, based
on the specific genetic alterations described above [7,9].
However, most studies have been descriptive and have not
attempted to develop and validate a molecular diagnostic
tool for chromosome copy number analysis to classify
diagnostically challenging tumors. In addition, a limita-
tion of array CGH is that it cannot detect regions of 'copy
neutral LOH' or acquired uniparental disomy (UPD)
which has been reported to constitute 50–80% of the
LOH in human cancers [10-13]. SNP arrays been used suc-
cessfully to detect structural variations in several types of
cancer, including RCC [8,11,14-19]. These arrays are sim-
ilar to array CGH in that fragmented genomic DNA is
amplified and applied to an array with the chromosomes
reassembled in silico. However, instead of cDNA or BAC
probes, SNP arrays use synthesized oligonucleotide
probes optimized to identify specific alleles at each SNP
locus. Thus, in addition to copy number information,
SNP arrays also provide genotypes which can be used to
determine regions of LOH. Other advantages include the
ability to use either fresh or paraffin-embedded tissues
[20-22], relatively low cost, good manufacturing practices,
and that they are amenable to scalability and automation.
Combined genome-wide copy number and LOH analysis
with SNP arrays has also been referred to as "molecular
allelokaryotyping" [23] and SOMA (SNP oligonucleotide
microarray analysis) [24]. The potential clinical applica-
tions for SNP microarrays in molecular oncology assays
are evident and we consider that this platform is suitable
for diagnostic/prognostic test development for chromo-
some copy number analysis of human tumors.
The purpose of this study was to assess the utility of SNP
array virtual karyotypes in the diagnosis of renal epithelial
tumors that are not readily classifiable by standard his-
topathologic evaluation. Our previous work has shown
that characteristic genetic lesions are readily identifiable
in morphologically classic renal epithelial tumors [8].
Here, we extend the classic morphology cohort (n = 50) as
well as assess the performance of the SNP array virtual
karyotype on 25 morphologically challenging renal epi-
thelial tumors. Our results indicate that virtual karyotypes
can be used to reduce uncertainty in the classification of
renal tumors and may be a useful ancillary study in clini-
cal practice.
Materials and methods
Tissue samples
Fifty tumors with classic morphology from the four most
common renal cell tumor subtypes (Clear Cell n = 21,
Papillary n = 9, Chromophobe n = 9 and Oncocytoma n
= 11) were used as a reference cohort to establish common
profiles for each group (Classic Morphology Cohort). Ref-Diagnostic Pathology 2008, 3:44 http://www.diagnosticpathology.org/content/3/1/44
Page 3 of 13
(page number not for citation purposes)
erence samples were obtained from the pathology
archives of the University of Pittsburgh Medical Center
(UPMC, Pittsburgh, PA), The Methodist Hospital (TMH,
Houston, TX), and Creighton University Medical Center
(CUMC, Omaha, NE). In addition, twenty-five (25) mor-
phologically challenging (MC) renal epithelial tumors
were obtained from the Health Sciences Tissue Bank of the
University of Pittsburgh. Samples were considered mor-
phologically challenging if they fit into the following 3
groups: A) a definitive diagnosis was rendered but uncer-
tainty in the diagnosis was expressed in the pathology
report (n = 12), B) a definitive diagnosis could not be ren-
dered after routine pathology examination but a favored
(or consistent with) diagnosis was indicated (n = 6) or C)
a diagnosis of an unclassified renal neoplasm was ren-
dered (n = 7). Samples were de-identified and obtained
under IRB approved protocols. All cases were reviewed by
at least two pathologists and specifically the challenging
cases were reviewed by genitourinary pathologists to con-
firm their status as diagnostically challenging. Ten 10 μm
slides were obtained for all samples with a corresponding
H&E stained slide. H&E stained tissue slides were evalu-
ated by a pathologist (FAM or JMH) for selection of areas
to be analyzed. Twenty of the samples with classic mor-
phology and 3 of the morphologically challenging cases
were described in a previous manuscript [8]. A summary
of the samples used in this study is presented in Table 1.
A complete list of samples belonging to the morphologi-
Table 1: Summary of tumor samples (n = 75)
Diagnosis Number of Samples Cohort (Morphology) T Stage (n)
Oncocytoma 11 Classic N/A
Renal Cell Carcinoma, Chromophobe 9 Classic T1b (2)
T2 (4)
T3a (2)
T3b (1)
Renal Cell Carcinoma, Clear Cell 21 Classic T1a (4)
T1b (7)
T2 (3)
T3a (4)
T3b (1)
T4 (1)
Renal Cell Carcinoma, Papillary Type 1 5 Classic T1b (2)
T2 (1)
T3b (1)
Renal Cell Carcinoma, Papillary Type 2 4 Classic T1a (1)
T1b (1)
T3b (2)
Oncocytic tumors, favor oncocytoma 5 Challenging N/A
Oncocytic/Eosinophilic tumors, favor carcinoma 10 Challenging T1a (3)
T1b (2)
T2 (2)
T3a (3)
Oncocytic/Granular tumors, favor chromophobe carcinoma 3 Challenging T1a (1)
T1b (2)
RCC, Unclassified 4 Challenging T2 (1)
T3a (2)
Mucinous, Tubular and Spindle cell carcinoma 1 Challenging T1b (1)
Papillary RCC 2 Challenging T1a (2)
*Note: A full list of all classic and challenging tumors in the study is available as Additional Table 1Diagnostic Pathology 2008, 3:44 http://www.diagnosticpathology.org/content/3/1/44
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cally "classic" and morphologically "challenging" cohorts
is available as Additional File 1.
Sample preparation and extraction
Tumor DNA was obtained from manually microdissected
10  μm paraffin sections according to a previously
described protocol for deparaffinization and DNA extrac-
tion [21]. DNA was quantitated on a NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, Wilming-
ton, DE). All samples processed for downstream analysis
in this study had an OD 260/280 ratio higher than 1.8.
SNP array assay
Samples were processed with an FFPE-optimized protocol
based on the GeneChip Mapping 10 K Xba Assay Kit
(Affymetrix, Santa Clara, CA) and whose performance has
been described previously [21]. All samples with 12 to 20
μg of PCR product were fragmented and labeled according
to the standard Affymetrix Genotyping protocol. The sam-
ples were then hybridized on GeneChip® Mapping 10 K
2.0 arrays (Affymetrix, Santa Clara, CA), for 16 h at 48°C
in a GeneChip® 450 hybridization oven (Affymetrix, Santa
Clara, CA) at 60 rpm. The arrays were washed and stained
according to the Affymetrix Genotyping protocol. The
SNP array data discussed in this manuscript have been
deposited in NCBI's Gene Expression Omnibus (GEO
http://www.ncbi.nlm.nih.gov/geo/) and are accessible
through GEO series accession numbers GSE9469.
Data analysis
Data acquired from the Affymetrix GeneChip Operating
System v4.0 (GCOS) was analyzed using Affymetrix Gene-
Chip Genotyping Analysis Software (GTYPE) 4.1. The
quality control parameters evaluated for each sample were
signal detection rate (the percentage of features in the
array that show adequate fluorescence intensity) and the
SNP call rate (rate of successful allele identification) [20].
Data from the X chromosome was not analyzed, as the
samples were not gender-matched. LOH and copy
number estimates were obtained using a publicly availa-
ble analysis package, Copy Number Analyzer for Affyme-
trix GeneChip arrays (CNAG 3.0) [25,26], as described
before [8]. All samples used in downstream analysis had
SNP call rates >85%.
Three pathologists participated in the assignment of con-
sensus performance scores for morphology, IHC, FISH,
and SNP arrays (FAM, AVP, JMH). A test was considered
'diagnostic' if information provided by the ancillary study
alone could enable a general surgical pathologist to cate-
gorize the tumor. The SNP-based virtual karyotype diag-
nosis was established by evaluating chromosomal
aberrations and LOH in each sample from the CNAG out-
put and determining the assignment to a tumor subtype
with the following criteria: -3p, clear cell carcinoma; +7/
+17, papillary carcinoma; -1, -2, -6, -17 (with or without -
10 or -13), chromophobe carcinoma; and -1 or normal/
diploid, oncocytoma. Chi-square contingency table anal-
ysis was performed using Stata (Version 10, College Sta-
tion, TX) to determine if tumor size (cm), Fuhrman
nuclear grade, organ confined (y/n), or low-high stage (I,
II vs. III, IV) was associated with chromosomal lesions
previously reported as having prognostic value.
FISH
Interphase FISH studies on renal tumors were performed
as part of the clinical diagnostic workup according to
standard protocols and results were obtained through de-
identified clinical records. The standard renal cell carci-
noma (RCC) FISH panel at UPMC consists of centromeric
probes for chromosomes 1, 2, 7, and 17. Formalin-fixed
paraffin-embedded sections, were mounted, and serially
sectioned at 5-mm intervals. H&E section was used by a
pathologist to determine the area of the tissue to be tar-
geted for analysis. FISH slides were deparaffinized in
xylene twice for 10 minutes, dehydrated twice with 100%
ethanol and then pretreated using the Vysis Paraffin Pre-
treatment Kit (Vysis, Inc., Downers Grove, IL). Slides were
digested for 18 minutes in protease solution (0.5 mg/ml)
at 37°C. FISH was performed using CEP1, CEP2, CEP7
and CEP17 centromere probes (Vysis, Inc.). The target
slide was denatured at 75°C for 5 minutes and dehydrated
in 70%, 85%, and 100% ethanol. Slides were incubated
with probe overnight at 42°C in a humidified chamber.
Post-hybridization washes were performed using 0.4×
SSC/0.3% Igepal (Sigma) at 72°C for 2 minutes, followed
by a room temperature 2 × SSC/0.1% Igepal wash for 30
seconds. Slides were air-dried in the dark and counter-
stained with DAPI (Vysis, Inc). Analysis was performed
using a Nikon Optiphot-2 (Nikon, Inc) and Quips
Genetic Workstation equipped with Chroma Technology
83000 filter set with single band excitors for Texas Red/
Rhodamine, FITC, DAPI (uv 360 nm) (Vysis, Inc). Only
individual and well delineated cells were scored. Overlap-
ping cells were excluded from the analysis. Approximately
60 cells were analyzed in the targeted region. By standard
clinical interpretative guidelines, chromosomal losses are
considered significant if present in greater than 30% of
cells. The loss is indeterminate if present in 20–30% of
cells. The loss is considered artifactual if seen in less than
20% of cells. Chromosomal gains are considered signifi-
cant if present in greater than 20% of cells. The gain is con-
sidered artifactual if seen in less than 20% of cells. If
multiple sections with different morphology were sub-
jected to FISH analysis for the same sample, the results
were averaged for each probe. The FISH-based diagnosis
was established by evaluating chromosomal losses in each
sample and determining the assignment with the follow-
ing criteria: -1 only or normal/diploid, oncocytoma; -1, -
2, and -17, chromophobe carcinoma; +7 and/or +17 pap-Diagnostic Pathology 2008, 3:44 http://www.diagnosticpathology.org/content/3/1/44
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illary carcinoma. Cases with results not fitting any of these
groups were deemed non-diagnostic.
Results
Classic morphology cohort
The chromosomal copy number aberrations and loci of
LOH derived using the SNP arrays were in agreement with
those reported in the literature for each subtype. Figure 1
summarizes the lesions detected in the 50 morphologi-
cally classic renal tumors in our study. Loss of all or part
of the short arm of chromosome 3 is a distinctive feature
of clear cell tumors, and was detected in all samples from
this group by the SNP arrays. The minimum region of loss
detected was from 3p21-p25. Seven out of eight papillary
carcinoma samples demonstrated the characteristic triso-
mies of chromosomes 7 and 17, while one papillary
tumor failed to show these aberrations and showed other
chromosomal changes, which have been reported previ-
ously for type 2 renal papillary carcinoma [27]. The
chromophobe carcinoma cohort showed losses affecting
chromosomes 1, 2, 6 and 17 in all tumors, in addition,
losses of 10 and 13 were observed in 8 of 9 tumors. Onco-
cytomas showed complete or partial loss of chromosome
1 in 82% of these tumors and no chromosomal copy
Cumulative frequency of chromosomal lesions in the four most common subtypes of renal epithelial tumors Figure 1
Cumulative frequency of chromosomal lesions in the four most common subtypes of renal epithelial tumors. 
Gains are indicated as positive values (light gray) and losses as negative values (dark gray). Hashed bars indicate lesions identi-
fied as copy neutral LOH.Diagnostic Pathology 2008, 3:44 http://www.diagnosticpathology.org/content/3/1/44
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number imbalances in 18%. Thus, tumors in this refer-
ence cohort show the characteristic virtual karyotype pro-
files that concur with morphology and permit
classification into each of the four most common diag-
nostic categories of renal cell neoplasms in 49/50 cases
(98%).
In addition to the characteristic changes reported, the SNP
arrays identified additional copy number aberrations.
Clear cell carcinomas showed trisomy 5 in 52% of cases
and gain of 5q in 76%, which makes +5q the second most
common chromosomal lesion in this tumor subtype.
Interestingly, trisomy 7, a chromosomal lesion mostly
associated with papillary RCC, was seen in 33% of clear
cell carcinomas. Chromosomal lesions previously
reported as associated with poor outcome in clear cell
tumors were identified in 43% (-14q) and 19% of patients
(-9q) [9,28] and only two cases showed concurrent loss of
14q and 9p. In this cohort, the presence of these lesions
was not associated with advanced stage (Stage I/II vs. III/
IV), higher nuclear grade or presence of metastasis (P >
0.05 with Fisher's exact test). Papillary RCC showed fre-
quent gains of chromosome 3 (+3q in 44%), trisomy or
partial gain of chromosome 12 (+12q in 56%) and tri-
somy 16 in 56% of cases. In chromophobe carcinomas,
loss of 21q was the most common lesion (56%) apart
from those that define this group. In oncocytomas, lesions
in 14q and chromosome 22 were observed, albeit at low
frequencies. A list of all chromosomal lesions seen in the
morphologically classic tumors summarized by chromo-
somal arm is available as Additional File 2.
Identification and implications of tumor subtype in the 
morphologically challenging cohort
In the morphologically challenging cohort, 22 out of 25
cases (88%) passed the quality thresholds for analysis as
described in methods. Repeat analysis of these three sam-
ples was not attempted. For the 22 cases used in the final
analysis, SNP arrays were able to identify genomic gain/
loss patterns that matched one of the classic patterns iden-
tified in the reference cohort in 86% (19 of 22). One of
the cases with non-classic genomic patterns matched the
published genomic profile for mucinous tubular and
spindle cell carcinoma (MTSCC) reported by Rokozy, et al
(monosomies in chromosomes 1, 4, 6, 8, 9, 13, 14, 15,
22) [29]. Thus, in 91% of these challenging cases with
adequate array results, a genomic pattern characteristic of
a known tumor type was identified (Table 2). MC09 could
not be classified due to showing a novel genomic profile
with mixed features for clear cell and chromophobe carci-
nomas. The second case that could not be classified
(MC12) showed a novel genomic profile with some fea-
tures of papillary renal carcinoma (+12, +16) with addi-
tional lesions not seen in other papillary tumors in the
classic morphology cohort (+5q, +9p with UPD, -17p,
del11q). Taking into account all cases (including those
that failed array quality thresholds) the virtual karyotype
was able to classify 80% of cases tested in the morpholog-
ically challenging cohort. Comparatively, FISH failed to
reliably detect classic genomic loss patterns in this cohort
(0/19) (Table 2). Screen shots of the actual virtual karyo-
types with the associated FISH data for each of the mor-
phologically challenging tumors are available as
Additional File 3.
All tumors in the morphologically challenging cohort
were, by definition, non-straightforward cases that
required ancillary studies and consultation with other
genitourinary pathologists. The final diagnoses ranged
from a qualified categorization (e.g., "most consistent
with" the diagnosis of x) to completely unclassifiable.
Often times the morphology, FISH, and IHC results sug-
gested conflicting diagnoses, which affected the certainty
of the diagnosis reported. Table 3 summarizes the results
of the virtual karyotype for each morphologically chal-
lenging tumor and gives the associated FISH results and
surgical pathology diagnosis. The potential impact of the
virtual karyotype, had it been available, is estimated by
determining whether the results confirmed the patholo-
gists' favored diagnosis (confirms), provides results that
are discrepant with the final diagnosis (discrepant), were
able to classify the tumor when it could not be classified
by standard pathologic criteria (SNP diagnostic), or iden-
tified a clear, but "novel" pattern that was not seen in the
morphologically classic cohort (novel). The diagnostic
implications of the virtual karyotypes in the 22 morpho-
logically challenging tumors is summarized in Table 4.
There were 13 virtual karyotypes that supported the diag-
nosis that the pathologist favored despite the implicit
uncertainty. He or she may have been able to provide a
Table 2: Performance of Molecular Ancillary Studies for Diagnosis of Renal Cell Tumors
Cohort (n) Morphology Diagnostic SNP Diagnostic FISH Diagnostic*
Classic (50) 50 49/50 98% 3/18 17%
Challenging (25) 0 20/22 91% 0/19 0%
Total (75) 50 69/72 96% 3/37 8%
*Not all samples have clinical data for FISH.D
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Table 3: FISH panel and virtual karyotype results for 22 morphologically challenging renal tumors
Sample ID Histologic Diagnosis FISH Virtual Karyotype Virtual Karyotype 
Interpretation
Array Result vs. 
Final Diagnosis*
Outcome Months 
Follow up
MC01 Low grade neoplasm, favor 
oncocytoma
Not done -1, -14, -21 Oncocytoma Confirms No evidence of tumor 9
MC02 Low grade neoplasm, favor 
oncocytoma
Not done del(10)(p11.23-p14) Oncocytoma Confirms Disease status 
Unknown
1
MC09 Eosinophilic epithelial tumor 
morphologically consistent with 
eosinophilic renal cell carcinoma
-1 (44%), -2 (52%), -7 (38%), 
and -17 (88%)
-1, -1, -2, -3, +5, UPD 6, +7, 
-9, -9, -10p, -10p, 
del(10)(q24.33-qter), -11, -
11, +12, -13,-13, 
+15(q22.2-qter), +16p, -
17p, -17p, -17p, -17q, -17q, 
-18, +19, -21, -21, -22, -22, 
-22 | [inferred tetrasomy]
Mixed pattern 
CRCC/CHRCC = 
Unclassified
Novel pattern Local & regional lymph 
node recurrence 52 
months after 
nephrectomy Alive at 
last F/U
69
MC10 Oncocytic renal neoplasm, favor 
carcinoma
-1 (51%), 2 failed, +7 (21%), 
+7+7 (8%), +17 (30%) and 
intermediate -17(28%)
-1, -14 Oncocytoma SNP diagnostic No evidence of tumor 30
MC11 Renal cell carcinoma, clear cell 
type with focal granular 
(eosinophilic) morphology
CHRCC area: +2 (75%) with 
intermed -1, -7, -17; CRCC 
area: -1, -2, -17 
(34%, 36%, 30%)
UPD
(3)(p14.1-p13.2)
Clear Cell RCC Confirms No evidence of tumor 33
MC12 Eosinophilic variant of clear cell 
renal carcinoma with papillary 
features.
-2 (31%), -7 (37%), -17 (97%) del(4)(p15.1-pter), 
+5(q21.3-qter), +9p(UPD), 
del(11)(q13.3-qter), +12, 
+16, del(17p), +17(q21.32-
qter), +17(q21.32-qter), 
+20, -22
Novel, not 
consistent with clear 
cell
Novel pattern Never disease free. 
Deceased
2
MC13 Oncocytic renal cell carcinoma, 
most suggestive of eosinophilic 
variant of conventional clear cell 
carcinoma
-1 (97%), -2 (83%), -7 (70%), 
and -17 (97%)
UPD
(3)(p12.2-p24.1)
Clear Cell RCC Confirms No evidence of tumor 3
MC14 Chromophobe renal cell 
carcinoma
-1 (48%), -2 (50%), -7 (56%), 
and -17 (47%)
No detectable 
chromosomal abnormalities
Oncocytoma Discrepant No evidence of tumor 29
MC15 Renal cell carcinoma with 
morphologic features consistent 
with eosinophilic variant of clear 
cell carcinoma
-2 (37%), -7 (45%), -17 
intermediate (20%)
del(1)(p32.3-pter), 
del(3)(p12.2-pter)
Clear Cell RCC Confirms Never disease free. 
Deceased
19
MC16 Oncocytic renal epithelial 
neoplasm, favor chromophobe 
renal cell carcinoma with 
eosinophilic morphology
-1(48%), -2 (40%), -7 (36%), and 
-17 (42%)
-1p, -9q, +12, -18, -21 Oncocytoma (novel) Discrepant No evidence of tumor 30D
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MC18 Low grade carcinoma with 
myxoid matrix and spindle and 
tubular architecture
-1 (85%), -2 (67%), -7 (37%), 
and -17 (73%)
-1, -4, -6, -8, -9, -13, -14, -
15, -17, -22
MTSCC Confirms No evidence of tumor 19
MC19 Renal cell carcinoma with 
morphologic features of a 
chromophobe renal cell 
carcinoma. Multiple other 
tumors 
(2 papillary, 2 clear cell)
-1 (38%), -2 (42%), -7 (33%). 17 
failed.
-3p, +3q, +7, del(9)(p13.2-
p22.3)
Clear Cell RCC Confirms No evidence of tumor 21
MC20 Eosinophilic renal cell carcinoma Intermed -1 (25%), -2 (52%), -7 
(42%), -17
No detectable 
chromosomal abnormalities
Oncocytoma Discrepant No evidence of tumor 24
MC21 Oncocytic renal epithelial 
neoplasm
-1 (92%), -17 (37%), +7 (51%) -1,+7, +9p, -9q Oncocytoma (novel) SNP diagnostic No evidence of tumor 20
MC22 Renal cell carcinoma, unclassified -1 (45%), 12 (37%), -17 (50%); 
intermed -7 (22%)
+7, +16 Papillary RCC SNP diagnostic No evidence of tumor 20
MC23 Eosinophilic renal cell carcinoma -1 (49%), -2 (53%), -7 (49%), 
and -17 (74%)
No detectable 
chromosomal abnormalities
Oncocytoma Discrepant No evidence of tumor 22
MC24 Papillary renal cell carcinoma, 
type 2
-1 (48%), intermed -2 (23%), -7 
(26%)
+7, +12, +17 Papillary RCC Confirms No evidence of tumor 27
MC26 Renal clear cell carcinoma -2 intermed (23%). +7 (52%), -
17 (43%)
-3p, unable to interpret 
other changes
Clear Cell RCC Confirms No evidence of tumor 1
MC28 Renal oncocytoma -1 (37%), -2 (38%), -7 (30%), 
and -17 (55%)
No detectable 
chromosomal abnormalities
Oncocytoma Confirms No evidence of tumor 68
MC29 Papillary renal cell carcinoma, 
type II
-2 intermediate (20%),+7 
(30%), +7+7 (18%)
+7, +16q (high normal 
contamination)
Papillary RCC Confirms No evidence of tumor 16
MC30 Renal oncocytoma 1 -(41%), 2 failed, -7(34%), -
17(65%)
No detectable 
chromosomal abnormalities
Oncocytoma Confirms No evidence of tumor 71
MC31 Renal epithelial oncocytic 
neoplasm with features of an 
oncocytoma
-1 (67%), -2 (63%), -7 (42%), 
and -17 (40%)
No detectable 
chromosomal abnormalities
Oncocytoma Confirms No evidence of tumor 19
*Array Results vs. Final Diagnosis field summarizes the potential impact on diagnosis had the SNP array karyotype been available (confirms = virtual karyotype confirms the favored diagnosis; SNP 
diagnostic = the virtual karyotype could classify the tumor based on the pattern of genetic lesions while morphology with IHC and FISH could not; novel = new pattern seen on virtual karyotype and 
ambiguous morphology; discrepant = virtual karyotype diagnosis and morphologic diagnosis are discrepant).
Table 3: FISH panel and virtual karyotype results for 22 morphologically challenging renal tumors (Continued)Diagnostic Pathology 2008, 3:44 http://www.diagnosticpathology.org/content/3/1/44
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more confident final diagnosis had they had the results of
the virtual karyotype. There were 4 cases that were signed
out as a carcinoma (malignant) that have virtual karyo-
types consistent with a benign oncocytoma. There were no
cases signed out as a benign oncocytoma that had karyo-
types consistent with malignant types. Lastly, there were 3
cases that were signed out as unclassifiable tumors which
the SNP array virtual karyotype could classify the tumor.
Table 4: Diagnostic Implications of SNP Array Results in Morphologically Challenging Cohort*
Confirms Diagnosis* confirmed by SNP 13
Discrepant Diagnosis carcinoma (malignant), SNP OC (benign) 4
Discrepant Diagnosis OC, SNP carcinoma 0
SNP diagnostic RCC Unclassified**, SNP diagnostic 3
*Tumors were classified, but with uncertainty due to complex morphology and/or conflicting ancillary study results
**Tumors could not be classified by morphology and ancillary studies.
Representative tumors from the morphologically challenging cohort Figure 2
Representative tumors from the morphologically challenging cohort. A, B & C: Photomicrographs of oncocytic 
tumors (100×). MC20 and MC23 with diagnosis of eosinophilic renal cell carcinomas; MC16 diagnosed as oncocytic renal cell 
neoplasm, favor chromophobe carcinoma. a, b and c: whole genome view of virtual karyotypes of samples A, B and C respec-
tively. The virtual karyotypes for these tumors show chromosomal patterns consistent with those seen in oncocytomas. The 
uppermost plot for each sample represents the estimated copy number as a log 2 ratio averaged over 20 SNPs, color-coded 
Hidden Markov Model (HMM) for copy number (yellow = copy number 2, pink = copy number 3, aqua = copy number 1), 
color-coded HMM for LOH (yellow = no LOH, blue = LOH).Diagnostic Pathology 2008, 3:44 http://www.diagnosticpathology.org/content/3/1/44
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This classification would have given the surgeons and
oncologists a direction for treatment and follow up of
these patients had this assay been available. Figure 2
shows examples of tumors that were interpreted as malig-
nant (eosinophilic or unclassified carcinomas) but whose
virtual karyotypes suggest that they are oncocytomas.
In two cases where the SNP arrays suggested a diagnosis of
oncocytoma, the tumors showed chromosomal lesions
not observed in our reference (classic morphology)
cohort. These changes include +7, +9p, -9q, +12, and -18.
Chromosomal gains are rare in oncocytomas, but gains of
7, 14, 18 and 20 have been previously reported [30,31].
Gain of 9p with concurrent loss of 9q in one of these
tumors suggests the presence of an isochromosome 9p,
which has also been reported in oncocytomas [30]. Gain
of 12 and loss of 18 have not, to our knowledge been pre-
viously reported. Trisomy 7 and 12 have been reported in
the setting of familial oncocytomas, however, most famil-
ial tumors show no chromosomal abnormalities [32].
Interestingly, these two oncocytomas from our study with
more complex chromosomal patterns presented with
atypical clinical features. One of them, MC21, showed
invasion of the perirenal adipose tissue and was diag-
nosed as an unclassifiable renal epithelial neoplasm. The
other tumor, MC16, is from a patient who was diagnosed
with an ipsilateral oncocytoma 8 years earlier. Tumor
MC16 was diagnosed as an oncocytic renal tumor with a
differential diagnosis of chromophobe carcinoma versus
clear cell carcinoma. The virtual karyotype is not consist-
ent with either chromophobe carcinoma (1, 2, 6, 10, 13,
and 17) or a clear cell carcinoma (-3p, +5q), but rather is
most consistent with genetic lesions seen in oncocytomas
as described above (Figure 2c). It is unclear if these chro-
mosomal lesions are associated with a more "aggressive"
behavior in oncocytomas, however, at last follow-up (21
and 30 months after surgery), both patients were alive and
without evidence of tumor.
Discussion
Specific chromosomal abnormalities have been found in
different types of renal epithelial neoplasms that define
the four most common subtypes of renal tumors (clear
cell RCC, papillary RCC, chromophobe RCC, and oncocy-
toma) [4,9,33] and other less common subtypes such as
the mucinous, tubular and spindle cell carcinoma
(MTSCC) [29]. We and others have shown that these
abnormalities can be detected with array-based whole
genome copy number analysis [7-9], and that reliable
detection of copy number abnormalities in paraffin
embedded tissues can be performed with SNP genotyping
arrays without the need for patient-matched normal tissue
[21,22,25].
In addition to performing well on formalin-fixed paraffin
embedded tumors, a useful ancillary study for classifica-
tion of renal tumors needs to perform well on morpho-
logically challenging tumors, not just classic tumors
which can be reliably diagnosed by routine pathologic
examination of H&E stained slides. To address this issue,
we analyzed SNP array virtual karyotypes for 25 renal epi-
thelial tumors that could not be readily categorized by
standard pathology review and were confirmed to be
'morphologically challenging' by two independent geni-
tourinary pathologists. The diagnoses for these cases con-
veyed a degree of uncertainty in the diagnosis, even when
a tumor subtype was provided. Some tumors could sim-
ply not be categorized and were signed out as unclassifia-
ble renal tumors. SNP array virtual karyotypes were able
to categorize 91% of these challenging tumors whose
DNA was suitable for analysis (Table 2). The results of
these virtual karyotypes could have impacted patient
management had they been available as an ancillary study
at the time these tumors were diagnosed (Table 4).
As indicated in this study and reported by others, ancillary
studies currently used by pathologists, such as IHC and
FISH, while reliable when evaluating renal tumors with
classic morphology, often fail to unequivocally categorize
morphologically challenging renal tumors [34,35]. Inter-
phase FISH on paraffin-embedded tissues is known to be
technically demanding, time-consuming, and requires
complex protocols with difficult optimizations [36]. In
addition, the protocol and the interpretation of the results
are limited by the presence of necrosis and/or the section-
ing of nuclei. It has been reported that FISH on 5 um sec-
tions of paraffin embedded tissue can underestimate
chromosomal anomalies when compared to analysis of
entire nuclei (37, 38). This artifact may give an underesti-
mation of trisomies and overestimation of monosomies if
the dimensions of the analyzable nuclei are not correctly
evaluated [36]. In our study, when comparing to the SNP
array results, interphase FISH on paraffin embedded renal
tumors overestimated monosomies even with a conserva-
tive threshold (>30% of examined cell nuclei). Other
authors have reported better results for FISH when back-
ground signals in the normal kidney tissue are substracted
from the tumor [28]. Utilizing this approach could
improve the performance of FISH for resolving morpho-
logically challenging tumors.
Immunohistochemistry appears to be a reliable method
for identification of common variants but fails to resolve
oncocytic neoplasms and other less common renal tumor
subtypes [34]. By definition, the tumors assigned to the
morphologically challenging cohort could not be resolved
based on morphology and routinely available immuno-
histochemistry stains. The fact that these tumors were
investigated with IHC and still had some level of uncer-
tainty in the diagnosis reflects the limitation of this tech-
nique in this type of tumors.Diagnostic Pathology 2008, 3:44 http://www.diagnosticpathology.org/content/3/1/44
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In summary, we believe that virtual karyotyping is a
robust alternative to FISH and IHC for these types of diag-
nostic specimens. Even when considering samples with
poor quality DNA, we were able to identify diagnostic
chromosomal profiles in 80% of all cases, including rare
subtypes such as the above mentioned MTSCC. These data
suggest that SNP array virtual karyotypes would be a use-
ful ancillary study for increasing diagnostic certainty in
the pathologic evaluation of renal epithelial tumors.
Clinical significance of classification and prognosis
SNP array virtual karyotypes can reliably categorize renal
epithelial tumors, but what is the clinical significance of
correct categorization? Proper diagnosis is critical to
patient management decisions, and the SNP array karyo-
types can identify well-established genetic lesions that cat-
egorize each renal tumor into a subtype [8]. For example,
loss of 3p indicates that the tumor is a clear cell renal car-
cinoma and all of the clear cell carcinomas in our study
show a loss of 3p. It has been shown that on univariate
analysis, different histologic subtypes of renal cell tumors
have markedly different prognosis with 5-year disease spe-
cific survival of 100% for oncocytoma and chromophobe
RCC, 86% for papillary RCC, 76% for clear cell RCC and
24% for unclassified RCC [37]. However, the significance
of histologic type for prognosis has not been confirmed
on multivariate analysis, where TNM stage, nuclear grade
and necrosis are best predictors of poor outcome. How-
ever, most studies are limited by the low frequency of non
clear-cell histologic types and thus might be underpow-
ered to definitively evaluate the role of histologic subtype
as a prognostic factor [38]. Recent evidence suggests that
the histologic subtype can predict response to combined
immunotherapy [39]. In a study by Herrmann et al,
patients with papillary RCC showed no significant benefit
from combined IL-2/Interferon/5FU, and thus it is sug-
gested that specific treatments be evaluated on each histo-
logic subtype separately [40]. Importantly, new
therapeutic approaches are being evaluated in clinical tri-
als with strict inclusion criteria that include restriction of
histologic subtypes and thus this information has strong
implications on the therapeutic options for patients with
RCC [38,41]. Therefore, accurate classification of renal
tumors is important for patient management, as the mor-
phologic subtype of renal cell carcinoma has been shown
to be of prognostic significance [37] and some subtypes
require specific therapeutic management [39,40,42].
The role of additional genetic lesions
In addition to the 'disease-defining lesions' that permit
categorization of renal cell neoplasms, the SNP array kary-
otypes allow us to also see additional lesions in the
genome of these tumors.
Loss of the p arm of chromosome 9 and other non-char-
acteristic copy number alterations are quite frequent in
renal tumors and some have been associated with poor
prognosis (9q/14q deletions) or more favorable out-
comes (5q31-ter gains) in clear cell RCC [9,28,43-45].
Recently, Brunelli and colleagues confirmed the associa-
tion of 9p loss with lower 5-year cancer specific survival in
clear cell renal cell carcinoma [28]. Interestingly, in out
cohort, -14q was present in 62% (5/8) of stage III/IV
patients while it was only seen in 30% (4/13) of organ
confined tumors (stage I/II), although this association did
not reach statistical significance. However, determining
this association was not the goal of this study, and thus
the sample size was underpowered to detect it. The impor-
tance of these additional genomic lesions for clinical deci-
sion making is evolving and may soon be desirable to
assess in clinical samples. If the status of additional
genetic lesions has clinical utility, then it may be desirable
to obtain virtual karyotypes on all clear cell carcinomas,
not just the morphologically challenging tumors. Detect-
ing the constellation of genetic lesions present in an indi-
vidual tumor may enable us to provide additional
diagnostic, prognostic, and therapeutic information
which can enable the transition to personalized medicine
for renal tumors.
Limitations of SNP array virtual karyotypes for diagnostic 
molecular oncology
Array-based copy number platforms, whether standard
arrayCGH or SNP arrays, provide high-resolution,
genome-wide assessment of tumor genomes. However,
they do have limitations. Since array-based copy number
platforms provide relative copy number assessment of the
tumor genome, tetraploid genomes generate the same vir-
tual karyotype as a diploid genome. Although certain fea-
tures of the SNP array virtual karyotype can suggest
tetraploidy, such as a region of chromosomal loss that is
associated with partial maintenance of heterozygosity
[46]; tetraploidy cannot be reliably discerned from a sub-
clone and/or normal cell contamination. In addition,
since array-based copy number platforms reconstruct the
genome in silico from disrupted DNA, they cannot detect
inversions or balanced translocations.
The potential impact of SNP array virtual karyotypes to
diagnostic molecular pathology, particularly solid
tumors, is far reaching. SNP array karyotypes show prom-
ise as reliable, objective and relatively inexpensive diag-
nostic tools to interrogate the many genome-level events
occurring in neoplasia – useful even at relatively low den-
sities as described in this study. Although we highlight
application to renal epithelial tumors in this manuscript,
the possible applications to other cancers using low and
higher density SNP arrays is already being explored by us
and other authors [23,47-49].
Significant issues remain unanswered at key decision
points in the management of patients with renal neo-Diagnostic Pathology 2008, 3:44 http://www.diagnosticpathology.org/content/3/1/44
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plasms. Unclassified renal cell carcinoma is a clinically
relevant problem the impacts patient prognosis and treat-
ment decisions. In addition, the lack of reliable biomark-
ers that can predict RCC recurrence in clinically localized
tumors or that can predict therapeutic response have sub-
stantial impact in mortality. We believe that these issues
can benefit from a genomic approach to detect chromo-
somal abnormalities and that the SNP arrays can enable
the clinical application of this approach on renal epithe-
lial neoplasms.
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